Literature DB >> 17618522

Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome).

Jill L Ostrem1, William J Marks, Monica M Volz, Susan L Heath, Philip A Starr.   

Abstract

Idiopathic cranial-cervical dystonia (ICCD) is an adult-onset dystonia syndrome affecting orbicularis oculi, facial, oromandibular, and cervical musculature. ICCD is frequently difficult to treat medically. Deep brain stimulation (DBS) of the globus pallidus internus (GPi) is a highly effective treatment for idiopathic generalized dystonia, however less is known about the effect of GPi DBS on ICCD. In this article, we present the results from a pilot study assessing the effect of GPi DBS in a series of patients with ICCD. Six patients underwent bilateral stereotactic implantation of DBS leads into the sensorimotor GPi. Patients were evaluated with the Burke-Fahn-Marsden dystonia rating scale (BFMDRS) and Toronto western spamodic torticollis rating scale (TWSTRS) before surgery and 6 months postoperatively. At 6 months, patients showed a 72% mean improvement in the BFMDRS total movement score (P < 0.028, Wilcoxin signed rank test). The mean BFMDRS disability score showed a trend toward improvement (P < 0.06). The total TWSTRS score improved 54% (P < 0.043). Despite improvement in dystonia, mild worsening of motor function was reported in previously nondystonic body regions with stimulation in 4 patients. Although GPi DBS was effective in these patients, the influence of GPi DBS on nondystonic body regions deserves further investigation. 2007 Movement Disorder Society

Entities:  

Mesh:

Year:  2007        PMID: 17618522     DOI: 10.1002/mds.21580

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  48 in total

Review 1.  Meige syndrome: what's in a name?

Authors:  Mark S LeDoux
Journal:  Parkinsonism Relat Disord       Date:  2009-05-19       Impact factor: 4.891

Review 2.  Update on blepharospasm: report from the BEBRF International Workshop.

Authors:  Mark Hallett; Craig Evinger; Joseph Jankovic; Mark Stacy
Journal:  Neurology       Date:  2008-10-14       Impact factor: 9.910

Review 3.  Dystonia rating scales: critique and recommendations.

Authors:  Alberto Albanese; Francesca Del Sorbo; Cynthia Comella; H A Jinnah; Jonathan W Mink; Bart Post; Marie Vidailhet; Jens Volkmann; Thomas T Warner; Albert F G Leentjens; Pablo Martinez-Martin; Glenn T Stebbins; Christopher G Goetz; Anette Schrag
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

4.  The subthalamic nucleus in primary dystonia: single-unit discharge characteristics.

Authors:  Lauren E Schrock; Jill L Ostrem; Robert S Turner; Shoichi A Shimamoto; Philip A Starr
Journal:  J Neurophysiol       Date:  2009-10-21       Impact factor: 2.714

Review 5.  Deep brain stimulation: current and future clinical applications.

Authors:  Mark K Lyons
Journal:  Mayo Clin Proc       Date:  2011-06-06       Impact factor: 7.616

6.  Micrographia induced by pallidal DBS for segmental dystonia: a subtle sign of hypokinesia?

Authors:  Christian Blahak; Hans-Holger Capelle; Hansjoerg Baezner; Thomas M Kinfe; Michael G Hennerici; Joachim K Krauss
Journal:  J Neural Transm (Vienna)       Date:  2011-01-19       Impact factor: 3.575

7.  Deep-Brain Stimulation for Basal Ganglia Disorders.

Authors:  Thomas Wichmann; Mahlon R Delong
Journal:  Basal Ganglia       Date:  2011-07-01

Review 8.  Unusual complications of deep brain stimulation.

Authors:  Fumin Tong; Adolfo Ramirez-Zamora; Lucy Gee; Julie Pilitsis
Journal:  Neurosurg Rev       Date:  2014-10-25       Impact factor: 3.042

9.  Induction of bradykinesia with pallidal deep brain stimulation in patients with cranial-cervical dystonia.

Authors:  Brian D Berman; Philip A Starr; William J Marks; Jill L Ostrem
Journal:  Stereotact Funct Neurosurg       Date:  2009-01-28       Impact factor: 1.875

Review 10.  Treatment strategies for dystonia.

Authors:  Leslie J Cloud; H A Jinnah
Journal:  Expert Opin Pharmacother       Date:  2010-01       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.